Visit BUHLMANN at CDDW 2020

2020-CDDW-Montreal QC

Canadian Digestive Diseases Week (CDDW) 2020

BUHLMANN Diagnostics Corp
Booth: #13
Feb 28 – Mar 1, 2020 | Fairmont Queen Elizabeth | Montreal, Quebec

Visit our booth to get an update on our Calprotectin and Therapeutic Drug Monitoring product portfolio:

IBDoc®, the first in-vitro diagnostic POC and home testing device to measure the inflammatory marker, fecal calprotectin.

BÜHLMANN IBDoc® is an in vitro diagnostic immunoassay for the quantitative determination of fecal calprotectin in human stool. The results of the assay are analyzed by a downloadable smartphone application. IBDoc® is intended as an aid to the determination of the inflammatory status of the patient’s intestinal mucosa for inflammatory bowel disease (e.g. Crohn’s Disease and Ulcerative Colitis) monitoring. IBDoc® is an assay developed for self-testing / home use by trained patients ages 12 and above that are under the care of a healthcare practitioner. The test may also be used in a near-patient or laboratory setting.


Health Canada Licence: 98903, Device class: 3

BÜHLMANN IBDoc® is not available for sale in the US.

Quantum Blue® platform offering rapid and quantitative results for serum calprotectinCRP, serum infliximab trough levels, and serum adalimumab trough levels (Additional trough level assays coming soon!)


Health Canada Licenses:
Quantum Blue® Infliximab: 98838
Quantum Blue® Adalimumab: 101776

Quantum Blue®Infliximab and Quantum Blue® Adalimumab is for Research Use Only in the US. Not for use in diagnostic procedures.

Click & Contact CDDW 2020 BUHLMANN Team

Connect with our team ahead of time, learn more about our assays or schedule a meeting!

Collin Shaw, VP of Business Development

VP of Business Development